Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average rating of “Moderate Buy” from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $41.8333.

A number of equities analysts recently weighed in on STOK shares. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Needham & Company LLC boosted their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, March 17th. Wedbush boosted their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Wolfe Research began coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $40.00 target price on the stock.

Stoke Therapeutics Stock Performance

STOK opened at $29.82 on Monday. The firm has a market capitalization of $1.86 billion, a PE ratio of -10.61 and a beta of 1.17. Stoke Therapeutics has a twelve month low of $11.17 and a twelve month high of $40.22. The firm’s 50-day moving average price is $32.24 and its 200 day moving average price is $32.37.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. As a group, analysts predict that Stoke Therapeutics will post -3.22 earnings per share for the current fiscal year.

Insider Activity

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total transaction of $145,041.52. Following the transaction, the general counsel directly owned 28,836 shares of the company’s stock, valued at $903,720.24. The trade was a 13.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $60,517.54. Following the transaction, the insider directly owned 10,276 shares in the company, valued at $322,049.84. This trade represents a 15.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 33,291 shares of company stock valued at $1,064,065 over the last three months. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC purchased a new position in Stoke Therapeutics during the fourth quarter worth about $26,000. KBC Group NV purchased a new stake in shares of Stoke Therapeutics in the 1st quarter valued at approximately $36,000. Harbour Investments Inc. raised its stake in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after acquiring an additional 898 shares during the period. Generali Investments Management Co LLC purchased a new stake in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $41,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.